IP Library Granted Patent US 9,848,807
Granted Patent B2
US 9,848,807 · App. 14/599,342 · Granted Dec 26, 2017

Tissue profile wellness monitor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,848,807
App. No.
14/599,342
Granted
Dec 26, 2017
Kind
B2
Abstract

A tissue profile wellness monitor measures a physiological parameter, generates a tissue profile, defines limits and indicates when the tissue profile exceeds the defined limits. The physiological parameter is responsive to multiple wavelengths of optical radiation after attenuation by constituents of pulsatile blood flowing within a tissue site. The tissue profile is responsive to the physiological parameter. The limits are defined for at least a portion of the tissue profile.

Claims (42)

1. A patient monitor comprising:

a front-end interface configured to receive, from a sensor comprising a light source that emits light into a tissue site of a patient and a detector that detects a plurality of wavelengths of the emitted light after attenuation by the tissue site, a signal indicative of the detected light at each of the plurality of wavelengths; and

a processor configured to:

determine, at each of the plurality of wavelengths and based on the signal, normalized plethysmographs (NPs);

normalize each of the determined NPs based on a reference wavelength;

determine a tissue profile curve based on the normalized NPs at the plurality of wavelengths;

analyze a shape of the tissue profile curve relative to a predefined boundary curve to determine patient wellness; and

output an indication in response to determining the shape of the tissue profile curve exceeds the predefined boundary curve.

2. The patient monitor of claim 1 , wherein the indication comprises at least one of a display, an alarm, a diagnostic, or a control.

3. The patient monitor of claim 1 , wherein determining the tissue profile curve comprises:

measuring, from the signal, values indicative of an amount of light attenuation for at least some of the plurality wavelengths;

defining, based on characteristics of the tissue site, additional values corresponding to at least a portion of a wavelength spectrum between the respective wavelengths associated with the at least some of the plurality of wavelengths; and

combining the measured values at each of the at least some of the plurality wavelengths with the additional values.

4. The patient monitor of claim 1 , wherein the processor is further configured to:

output a first signal indicative of patient normalcy when the tissue profile curve is within the predefined boundary curve and a rate of change of the tissue profile curve is less than a maximum rate of change; and

output a second signal indicative of alert when at least a portion of the tissue profile curve is outside of the predefined boundary curve and the rate of change of the tissue profile curve is greater than the maximum rate of change.

5. The patient monitor of claim 1 , wherein the tissue profile curve is indicative of at least one of oxygen saturation of the patient, carboxyhemoglobin of the patient, or methemoglobin of the patient.

6. The patient monitor of claim 1 , wherein the tissue profile curve comprises a first portion and a second portion, and wherein the first portion is analyzed in comparison to a first portion predefined boundary curve, and the second portion is analyzed in comparison to a second portion predefined boundary curve.

7. The patient monitor of claim 6 , wherein the processor is further configured to:

provide a first indication in response to the first and second portions not exceeding the respective first and second portion predefined boundary curves;

provide a second indication in response to one of the first or second portions exceeding the respective first or second portion predefined boundary curves; and

provide a third indication in response to both of the first and second portions exceeding the respective first and second portion predefined boundary curves.

8. The patient monitor of claim 1 , wherein the reference wavelength is one of the plurality of wavelengths.

9. A patient monitor comprising:

a front-end interface configured to receive, from a sensor comprising a light source that emits light into a tissue site of a patient and a detector that detects a plurality of wavelengths of the emitted light after attenuation by the tissue site, a signal indicative of the detected light at each of the plurality of wavelengths; and

a processor configured to:

determine, at each of the plurality of wavelengths and based on the signal, normalized plethysmographs (NPs);

normalize each of the determined NPs based on a reference wavelength;

determine a tissue profile curve indicative of a relationship among the normalized NPs at the plurality of wavelengths;

evaluate a trend in movement of the tissue profile curve relative to a predetermined trend limit to determine patient wellness; and

output an indication in response to determining the trend in movement of the tissue profile curve exceeds the predetermined trend limit.

10. The patient monitor of claim 9 , wherein the trend in movement of the tissue profile curve exceeding the predetermined trend limit indicates advance warning of deteriorating patient wellness.

11. The patient monitor of claim 9 , wherein the reference wavelength divides the tissue profile curve into a first portion and a second portion, and wherein the first portion is evaluated in relation to a first portion predetermined trend limit, and the second portion is evaluated in relation to a second portion predetermined trend limit.

12. The patient monitor of claim 11 , wherein the processor is further configured to:

provide a first indication in response to the first and second portions not exceeding the respective first and second portion predetermined trend limits;

provide a second indication in response to one of the first or second portions exceeding the respective first or second portion predetermined trend limits; and

provide a third indication in response to both of the first and second portions exceeding the respective first and second portion predetermined trend limits.

13. The patient monitor of claim 9 , wherein the reference wavelength is one of the plurality of wavelengths.

14. The patient monitor of claim 9 , wherein determining the tissue profile curve indicative of the relationship among the normalized NPs at the plurality of wavelengths comprises:

defining continuous normalized NP values corresponding to at least a portion of a wavelength spectrum between the two or more of the at least some of the plurality of wavelengths based at least in part on characteristics of the tissue site; and

combining the normalized NP values at each of the at least some of the plurality of wavelengths with the defined continuous normalized NP values.

15. The patient monitor of claim 9 , wherein the tissue profile curve is indicative of at least one of oxygen saturation of the patient, carboxyhemoglobin of the patient, or methemoglobin of the patient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2016
From: CERCACOR LABORATORIES, INC.
To: MASIMO CORPORATION
Reel/Frame 038049/0074 →